Journal Article

Determination of Methylene Blue and Leucomethylene Blue in Male and Female Fischer 344 Rat Urine and B6C3F<sub>1</sub> Mouse Urine

Norman F. Gaudette and Jon W. Lodge

in Journal of Analytical Toxicology

Volume 29, issue 1, pages 28-33
Published in print January 2005 | ISSN: 0146-4760
Published online January 2005 | e-ISSN: 1945-2403 | DOI:
Determination of Methylene Blue and Leucomethylene Blue in Male and Female Fischer 344 Rat Urine and B6C3F1 Mouse Urine

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)


Show Summary Details


A liquid chromatographic method for the determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and male and female B6C3F1 mouse urine was developed for use in supporting toxicokinetic studies, validated, and used to analyze urine samples for a preliminary dose level range-finding study. The method was validated for a concentration range of 10.0 to 20,000 ng/mL in urine. Samples up to 75,000 ng/mL demonstrated good recoveries when diluted into the range of the calibration curve. Six sets of calibration standards were prepared in F344 male rat urine for analysis to demonstrate reproducibility and ruggedness. The stability of sample extracts was determined under various storage conditions. During the course of analyses of the animal samples, a possible metabolic process was observed. Although Azure B is a significant impurity in methylene blue trihydrate, the amount of Azure B seen in urine samples collected from rodents dosed with methylene blue trihydrate is significantly greater than the amount seen in rodent urine spiked directly with methylene blue. This observation suggests possible N-demethylation of the methylene blue as a metabolic transformation to Azure B.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.